Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

C-Myc facilitates prediction of "7+3" induction failure in de novo acute myeloid leukaemia with high-risk cytogenetics

ABSTRACT: c-Myc facilitates prediction of "7+3" induction failure in de novo acute myeloid leukaemia with high-risk cytogenetics

PROVIDER: PRJNA692419 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

c-Myc facilitates prediction of "7+3" induction failure in de novo acute myeloid leukaemia with high-risk cytogenetics

Project description:This study aimed to identify whether c-Myc could facilitate prediction of "7+3" induction failure in de novo acute myeloid leukaemia (AML) with high-risk cytogenetics. Seventy-five untreated de novo AML patients who completed the "7+3" induction therapy were enrolled (24 patients from a prospective cohort; 51 patients from a retrospective cohort) and stratified into complete remission (CR) and non-CR groups. Myc-associated molecular signature between the CR and non-CR groups in the prospective cohort was compared after gene set enrichment analysis. c-Myc protein expression was assessed via immunohistochemical staining. A high c-Myc-immunopositivity was defined when ≥ 40% of bone marrow myeloblasts were c-Myc (+). Our results revealed that AML patients who did not achieve CR by the "7+3" induction therapy had a higher Myc gene expression than those that achieved CR (p=0.047). Myc gene expression was positively correlated with c-Myc protein expression (p=0.014). Although the non-CR group did not have more c-Myc protein expression compared to that in the CR group (p=0.151), combination of high c-Myc-immunopositivity and high-risk cytogenetics increased the probability of "7+3" induction failure compared to that in high-risk cytogenetics alone. Induction strategies other than “7+3” might be a solution for de novo patients with high c-Myc-immunopositivity and high-risk cytogenetics.

2021-04-01 | GSE164894 | GEO

Serum miRNA-based risk prediction for stroke

Project description:Serum miRNA-based risk prediction for stroke

| PRJNA480974 | ENA

De novo acute heart failure and acutely decompensated chronic heart failure.

Project description: Not available

| S-EPMC4452901 | biostudies-literature

Sampling bottlenecks in de novo protein structure prediction.

Project description: Not available

| S-EPMC2760740 | biostudies-literature

Generalized ensemble methods for de novo structure prediction.

Project description: Not available

| S-EPMC2631076 | biostudies-literature

GimmeMotifs: a de novo motif prediction pipeline for ChIP-sequencing experiments.

Project description: Not available

| S-EPMC3018809 | biostudies-other

De novo structure prediction and experimental characterization of folded peptoid oligomers.

Project description: Not available

| S-EPMC3437879 | biostudies-other

A New Biomarker Tool for Risk Stratification in "<i>de novo</i>" Acute Heart Failure (OROME).

Project description: Not available

| S-EPMC8793744 | biostudies-literature

OncoSig: a new algorithm for the accurate and systematic de novo prediction of Oncoprotein-centric Signaling networks

Project description:We introduce a new algorithm, OncoSig, to address the deficiencies of canonical pathways through the accurate, context-specific prediction of proteins representing both known and novel functional members of Oncoprotein-centric Signaling networks. OncoSig performs systematic, de novo elucidation of Protein-Centric molecular interaction maps (PC-maps), which include upstream modulators, cognate binding partners, and downstream effectors. The reconstructed KRAS PC-Map in lung adenocarcinoma (LUAD) demonstrates the recapitulation of known biology and, critically, the discovery of novel KRAS effectors that elicit synthetic lethality in LUAD organoid cultures. To illustrate the generalizability of OncoSig, the methodology is applied to elucidate the PC-maps of ten recurrently mutated oncoproteins and oncopathways in LUAD as well as KRAS PC-Maps across three tumor contexts. OncoSig thus reveals tumorigenic architecture to an unprecedented degree and provides a unique mechanistic perspective on how the flow of information in cells is dysregulated in support of tumor homeostasis. To validate predicted KRAS effectors in primary tumor organoid cultures, this study includes a pooled RNAi screening approach (shRNA-seq) in primary lung tumors from a mouse model driven by mutant Kras and p53 loss.

2020-11-11 | GSE107042 | GEO

De novo prediction of structured RNAs from genomic sequences.

Project description: Not available

| S-EPMC4712260 | biostudies-literature